The Patent Finder
NE

New England Biolabs, Inc.

Filings on record here from 2001, where this site's data begins
OverviewNotableFeesChangesFamiliesPatent listSources & methods

166 patents currently held

5 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
6 more records may belong here and await a decision; they are not counted.

The next term ends in Jan 2027. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
35
Ending by 2030
Jan 2027
Next term end
87
Patent families

When these terms end

Held patents by the year their term ends
notable patents fee due within 90 days all others Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Compositions and Methods for Analyzing Modified Nucleotides US 10,227,646
Cited by 44 later US patents, top 5% of utility patents granted in 2019 in our data, and renewed at 2 of 3 maintenance windows. Protection runs to 2036.
Ends Oct 2036 · High confidence
Also notable
Asymmetric Adapter Library Construction US 8,029,993
Cited by 42 later US patents, top 25% of utility patents granted in 2011 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2029.
Ends Aug 2029 · High confidence
Also notable
Rapid Diagnostic Test Using Colorimetric LAMP US 10,968,493
A family of 8 related applications built on the 2021 grant. Protection runs to 2040.
Ends Jul 2040 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 4 fees due Nov 21 to 28, 2026 · next Nov 21
  • 1 fee due Dec 6, 2026
    The maintenance fee for Fragmentation of DNA (US 11,667,968) comes due Dec 6, 2026. Unpaid by Jun 7, 2027, it lapses early.
  • 4 fees due Jan 7, 2027
  • 4 fees due Feb 1 to 22, 2027 · next Feb 1
  • 4 fees due Mar 1 to 29, 2027 · next Mar 1
  • 6 fees due Apr 1 to 30, 2027 · next Apr 1
  • 3 fees due May 24 to 28, 2027 · next May 24
  • 5 fees due Jun 1 to 30, 2027 · next Jun 1
  • 2 fees due Aug 2 to 23, 2027 · next Aug 2
  • 4 fees due Sep 24 to 26, 2027 · next Sep 24
  • 4 fees due Oct 14 to 28, 2027 · next Oct 14
  • 1 fee due Nov 14, 2027
    The maintenance fee for Tela Variants, Compositions, and Methods (US 11,981,936) comes due Nov 14, 2027. Unpaid by May 15, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 22, 2026
  • 2 terms have ended since Aug 22, 2026

What they patent

The largest of its 87 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 7,820,424Nicking Endonuclease Methods and Compositions
In force
 · High confidence
In forceHigh confidence
US 7,833,769Mcra Variants and Uses Thereof
In force
 · High confidence
In forceHigh confidence
US 8,058,029Method for Cloning and Expression of Stui Restriction Endonuclease and Stui Methylase in E. Coli
In force
 · Medium confidence
In forceMedium confidence
US 8,153,358Selection and Enrichment of Proteins Using in Vitro Compartmentalization
In force
 · High confidence
In forceHigh confidence
US 8,628,945High Fidelity Restriction Endonucleases
In force
 · High confidence
In forceHigh confidence
US 8,673,610High Fidelity Restriction Endonucleases
In force
 · High confidence
In forceHigh confidence
US 8,691,549High Fidelity Restriction Endonucleases
In force
 · High confidence
In forceHigh confidence
US 10,294,464High Fidelity Restriction Endonucleases
In force
 · High confidence
In forceHigh confidence
US 10,450,559High Fidelity Restriction Endonucleases
In force
 · High confidence
In forceHigh confidence
US 11,001,818High Fidelity Restriction Endonucleases
In force
 · High confidence
In forceHigh confidence
10 of 166 patents shown.
Pro members see all 166.
Pro members: see all 166 patents
Also on record, not counted in the 166: 5 patents in force now held by others · 54 patents ended · 47 applications pending · 70 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited